Aaron Goodman: HMA-Venetoclax-Ivosidenib in Frontline AML
Aaron Goodman, Hematologist/Oncologist and an Associate Professor of Medicine at the University of California, shared a post on X:
“HMA+ven+ivo frontline AML
1. Can’t believe they called regimen “well tolerated”
2. What we need to know is HMA+ven+ivo superior to HMA+ven followed by Ivo at relapse.
3. Hopefully well done RCT with good post protocol Ivo measuring OS answers question.”
Title: Outcomes of Frontline Triplet Regimens With a Hypomethylating Agent, Venetoclax, and Isocitrate Dehydrogenase Inhibitor for Intensive Chemotherapy–Ineligible Patients With Isocitrate Dehydrogenase–Mutated AML
Authors: Courtney D. DiNardo, Jennifer Marvin-Peek, Sanam Loghavi, Koichi Takahashi, Ghayas C. Issa, Wei-Ying Jen, Naval G. Daver, Patrick K. Reville, Nicholas J. Short, Koji Sasaki, Jillian K. Mullin, Corey A. Bradley, Gautam Borthakur, Abhishek Maiti, Yesid Alvarado, Naveen Pemmaraju, Hussein A. Abbas, Danielle E. Hammond, Fadi Haddad, Guillermo Montalban Bravo, Kelly S. Chien, Musa Yilmaz, Steven M. Kornblau, Elias Jabbour, Farhad Ravandi, Tapan Kadia, Guillermo Garcia-Manero, Marina Y. Konopleva, Hagop M. Kantarjian
More Posts Featuring Aaron Goodman on OncoDaily
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023